Ipsen and Debio link on research for compound that has the potential to target major human cancers

French drugmaker Ipsen  and Debiopharm Group, a Swiss biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, have entered an agreement under which Debiopharm is granted an exclusive worldwide license to develop and commercialize Ipsen's first-in-class inhibitor of the CDC25 phosphatase enzyme (now Debio 0931), for the treatment of various human cancers.

CDC25 is a key enzyme involved in the regulation of cell cycle. Its over-expression is associated with the progression of cancer. By blocking the cell cycle and thus interrupting tumor growth, Debio 0931 represents a promising novel target for cancer therapies. This preclinical candidate will now be the subject of a full development program under the responsibility of Debiopharm.

Under the terms of the agreement, Debiopharm will be exclusively responsible for the development of Debio 0931, with Ipsen having an option to re-acquire development and commercialization rights post completion of Phase II clinical trials. Ipsen will receive an upfront payment and be eligible for milestone payments and royalties. Further financial details of the deal were not disclosed.